After FDA's blessing, can Cardinal take Navidea's Lymphoseek to sales heaven?
This article was originally published in Scrip
Executive Summary
On a day when the news around the world was overshadowed by the election of 266th Catholic pope, the FDA granted its own blessing to Navidea Biopharmaceuticals to market Lymphoseek (tilmanocept), a first-of-its-kind receptor-targeted radiopharmaceutical agent, which will be sold and distributed in the US by the company's ordained partnerCardinal Health – one among the trinity of big US wholesalers.